Please refer to ClinicalTrials.gov : NCT03716570.
Phase 1
Completed
- Conditions
- Parkinson's disease
- Registration Number
- JPRN-jRCT2080224171
- Lead Sponsor
- Biogen Japan Ltd.
- Brief Summary
BIIB054 is generally safe and tolerable up to 3500 mg in Japanese participants with early PD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Please refer to ClinicalTrials.gov : NCT03716570.
Exclusion Criteria
Please refer to ClinicalTrials.gov : NCT03716570.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety
- Secondary Outcome Measures
Name Time Method safety<br>pharmacokinetics